Former biologics boss Peter Marks had a vision. With the FDA’s latest draft guidance, it’s coming to fruition. Speaking with BioSpace, current CBER leader Karim Mikhail said the “adapted pathway” is ...
With companies including AstraZeneca, Pfizer and Revolution Medicines clamoring to get in on Summit Therapeutics’ ...
Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) today announces that regulatory filings for ORPATHYS ® (savolitinib) in ...
New fixed, single-room configuration is designed to make DeepOCT+NIRS Imaging and X1-FFR physiology readily available for ...
Exploratory research in mSystems finds broader small-bowel gene-expression changes in ISO than in methanogen overgrowth or ...
Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, ...
SonicForce is an investigational coronary intravascular lithotripsy (IVL) system that uses acoustic pressure waves, similar ...
The Foundation's CLIA-certified laboratory combines DNA methylation profiling, MGMT status, copy-number variation analysis ...
INOVIO delivers a new nonsurgical treatment option with a broad indication for adults living with RRP, a rare and ...
Analyses presented at TCT highlight how patient selection, timely Impella support and consistent care protocols may help ...
If approved, BridgeBio Pharma’s BBP-418—which, according to one Jefferies analyst, boasts “pretty darn compelling” data—would ...
The live webcasts can be accessed on the company’s investor relations website at investors.gilead.com. The replays will be ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results